Sulfamazone
Chemical compound
- J01ED09 (WHO)
- (1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-{[4-[(6- methoxypyridazin-3-l)sulfamoyl]phenyl]amino} methanesulfonic acid
- 65761-24-2
- 187764
- 163211
- D7B8U8VA9J
- D07241 Y
- CHEBI:131721
- ChEMBL2104921
- DTXSID50867180
- Interactive image
- CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(NC3=CC=C(C=C3)S(=O)(=O)NC4=NN=C(C=C4)OC)S(=O)(=O)O
InChI
- InChI=1S/C23H24N6O7S2/c1-15-21(23(30)29(28(15)2)17-7-5-4-6-8-17)22(38(33,34)35)24-16-9-11-18(12-10-16)37(31,32)27-19-13-14-20(36-3)26-25-19/h4-14,22,24H,1-3H3,(H,25,27)(H,33,34,35)
- Key:BGLHAKAJGYLSOX-UHFFFAOYSA-N
Sulfamazone (INN) is a sulfonamide antibiotic with antipyretic properties.[1]
References
- ^ Zhao Z, Dai X, Li C, Wang X, Tian J, Feng Y, et al. (January 2020). "Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect". European Journal of Medicinal Chemistry. 186: 111893. doi:10.1016/j.ejmech.2019.111893. PMC 7115706. PMID 31761383.
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor | |||||||||
---|---|---|---|---|---|---|---|---|---|
Sulfonamides (DHPS inhibitor) |
| ||||||||
Combinations |
| ||||||||
Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation | |||||||||
---|---|---|---|---|---|---|---|---|---|
Fluoroquinolones |
| ||||||||
Newer non-fluorinated | |||||||||
Related (DG) |
inhibitors
Nitroimidazole derivatives |
---|
Rifamycins/ RNA polymerase | |
---|---|
Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e